efocipegtrutide
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 4, 2018 (NCT03374241)
Timeline
Indications
Mechanism of action
GIP agonist
GLP1R agonist
- Glucagon receptorAGONIST
GCGR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095149 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04505436 | Phase 2 | Jul 29, 2020 | Hanmi Pharmaceutical |
| NCT03744182 | Phase 1 | Nov 1, 2018 | Hanmi Pharmaceutical |
| NCT03374241 | Phase 1 | Apr 4, 2018 | Hanmi Pharmaceutical |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 3 | 3 | 2 | 2018 |
1 organizations
Page 1 / 1